284462-44-8

Upstream product

• 17609-80-2 4-amino-3-chlorophenol 
• 7440-44-0 pyrographite 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 41513-02-4 4-bromo-3-(trifluoromethyl)phenyl isocyanate 
• 284462-45-9 4-chloro-2-methoxy-5-(trifluoromethyl)phenylaniline 
• 284462-99-3 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate 
• 284462-43-7 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chlorophenyl-(2,2,2-trifluoro)acetamide 

Downstream Products

• 284462-92-6 3-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-4-methylaniline 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284462-83-5 4-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-3-chloroaniline 

Relevant academic research and scientific papers

HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER

The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}-carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-carboxamide and alternatives forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and metabolites); pharmaceutical compositions which contain them and methods for treating cancer using them.

6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.

Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.